Healthcare stock to watch: Medtronic PLC (NYSE: MDT)

Free $100 Forex No-Deposit Bonus

Medtronic PLC (NYSE: MDT) reported better than expected results for the second quarter of FY 20 and raised its full-year profit outlook boosted by strong performance in its unit that makes surgical instruments. The company’s net income for the quarter rose to $1.36 billion from $1.12 billion, in the year-ago period. For the second quarter, the company posted the 61% growth in Cash Flow from Operations to $1.9 Billion and 66% increase in the Free Cash Flow to $1.6 Billion.

In the Minimally Invasive Therapies Group, the company had another very strong quarter, as it grew 6.1% and ahead of expectations, on the back of strong performances in both surgical innovations and RGR.

In Surgical innovations, the company has grown by mid-single-digits in both Advanced Stapling and Advanced Energy. Advanced Stapling growth is due to the new products in the Tri-Staple line, including the EEA circular stapler and Tri-Staple 2.0 re-loads.

Advanced Energy grew due to the continuous innovation in the LigaSure Franchise, including the LigaSure Exact Dissector. Respiratory GI and Renal grew 6.1% in the quarter. The GI Solutions business grew high single-digits due to strong sales of Bravo calibration-free reflux system, EndoFLIP imaging systems and PillCam systems. Respiratory and patient monitoring also posted the growth in high-single-digits, due to Nellcor Pulse Oximetry, Microstream capnography, and BIS brain monitoring consumables, Puritan Bennett 980 ventilators and McGRATH video laryngoscopes.

In the Cardiac and Vascular Group, the company grew 1.3% in the quarter, which was in line with the company’s expectations

MDT in the second quarter of FY 20 has reported the adjusted earnings per share of $1.31, beating the analysts’ estimates for the adjusted earnings per share of $1.28, according to the FactSet consensus. The company had reported the adjusted revenue growth of 3 percent to $7.71 billion in the second quarter of FY 20, beating the analysts’ estimates for revenue of $7.66 billion. The minimally invasive therapies business, has posted the revenue of $2.14 billion, ahead of analysts’ average estimate of $2.13 billion, according to IBES data from Refinitiv.

But its cardiac and vascular unit missed estimates for revenue as it reported the revenue of $2.86 billion, while analysts had expected $2.87 billion.

For fiscal 2020, the company has affirmed its revenue growth outlook of 4% but raised its adjusted earnings per share guidance range to $5.57 to $5.63 from $5.54 to $5.60. The analysts were expecting full-year earnings of $5.56 per share.

Copyright © 2020. All Rights Reserved. FXDailyReport.Com
Risk Warning: Trading CFDs is a high risk activity and you may lose more than your initial deposit. You should never invest money that you cannot afford to lose. will not accept any liability for loss or damage as a result of reliance on the information contained within this website including data, quotes, charts and buy/sell signals. Please be fully informed regarding the risks and costs associated with trading the financial markets.